Clinical trials
Phase 3 Cardiovascular Diseases trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
68 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2003 | 5 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 7 |
| 2011 | 4 |
| 2012 | 6 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 5 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 39 |
| Terminated | 13 |
| Recruiting | 8 |
| Active, not recruiting | 5 |
| Unknown status | 2 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 6 |
| GlaxoSmithKline | 5 |
| Novartis Pharmaceuticals | 5 |
| Eli Lilly and Company | 4 |
| Amgen | 3 |
| Hoffmann-La Roche | 3 |
| Hamilton Health Sciences Corporation | 2 |
| National Heart, Lung, and Blood Institute (NHLBI) | 2 |
| Ottawa Heart Institute Research Corporation | 2 |
| Pfizer | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cardiovascular Diseases | 68 |
| Myocardial Infarction | 14 |
| Atherosclerosis | 13 |
| Diabetes Mellitus, Type 2 | 13 |
| Heart Diseases | 12 |
| Stroke | 11 |
| Coronary Disease | 9 |
| Hypertension | 9 |
| Diabetes Mellitus | 7 |
| Acute Coronary Syndrome | 6 |
Trials
Showing 1 to 25 of 68. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.